{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-012128","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.610564+00:00","generated_at":"2026-06-05T00:23:58.922097+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocuphire Pharma reports FY 2023 net loss of $10M; advances APX3330 Phase 3 and RYZUMVI launch","bullets":["Cash $50.5M at Dec 31, 2023; management expects to fund operations into mid-2025.","FY 2023 revenue $19.0M (incl. $10M Viatris milestone) vs $39.9M in 2022; net loss $10.0M ($0.46/share) vs net income $17.9M in 2022.","APX3330 SPA submitted for Phase 3 registrational trial in diabetic retinopathy; FDA agreed on primary endpoint.","RYZUMVI (phentolamine) approved Sep 2023; launch expected H1 2024; Viatris to fund further development for presbyopia and post-refractive surgery.","Leadership changes: George Magrath CEO (Nov 2023), new CFO and CSDO appointed Feb 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-012128","json":"https://secwatch.observer/filing/0001140361-24-012128.json","markdown":"https://secwatch.observer/filing/0001140361-24-012128.md","text":"https://secwatch.observer/filing/0001140361-24-012128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124012128/0001140361-24-012128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124012128/ef20023531_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:23:58.922097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d95cd0cf64cfadec0d02996e1bae31082aecbf1","claim":"Opus Genetics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $1.7 million and $19.0 million for the fourth quarter and year ended December 31, 2023, respectively.","evidence_excerpt":"On March 8, 2024, Ocuphire Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124012128/0001140361-24-012128-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$1.7 million and $19.0 million for the fourth quarter and year ended December 31, 2023, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}